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Highlights:
 GO, MGO and 3-DG withstand in vitro gastrointestinal digestion 
 Digested 1,2-dicarbonyl compounds reduce number and activity of gut 
microorganisms
 For the first time, the role of 3-DG in modifying the gut microbial levels has been 
shown
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This study, investigated the stability of dicarbonyl compounds (DCs), 3-deoxyglucosone 
(3-DG), glyoxal (GO) and methylglyoxal (MGO) during simulated gastrointestinal 
digestion processes and the impact these compounds have on the gut microbiota. DCs 
pass almost unaltered through the in-vitro gastrointestinal digestion phases 
(concentration loss: 11% for 3-DG, 24% for GO and MGO) and have an effect on the 
fermentative digestion process, reducing the total gut bacterial population up to 6 Log10 
units. Previous studies have shown no antimicrobial activity for 3-DG, however, for the 
first time it has been shown that when incubated with faecal bacteria 3-DG strongly 
depressed this microbial community. 
The influence of dicarbonyl compounds on the anaerobic fermentation processes was 
confirmed by the reduced production of short-chain fatty acids. Considering the modern 
Western diet, characterised by high consumption of ultra-processed foods rich in 
dicarbonyl compounds, this could lead to a reduction of bacteria important for the 
microbiome.
Keywords




The human gut is colonised by an enormous number of microorganisms, mainly bacteria 
and, it is estimated that the microbiota of a human adult is composed of ~1014 bacterial 
cells (Zhu, Wang & Li, 2010). The composition, as well as the ratio of different species 
forming the intestinal microbiome, is very diverse within the human population (Dicksved, 
2008) and influenced by multiple factors, such as age, origin, environment and dietary 
habits. Owing to the multitude of direct and indirect interactions with the host organism, 
the intestinal microbiome is closely linked to host health (Saarela, Lähteenmäki, 
Crittenden, Salminen & Mattila-Sandholm, 2002; Del Rio, Rodriguez-Mateos, Spencer, 
Tognolini, Borges & Crozier, 2013).
Several studies have investigated the impact of diety nutraceuticals on the microbiota, 
such as polyphenols, prebiotics and polyunsaturated fatty acids (Duda-Chodak, Tarko, 
Satora & Sroka, 2015 and references therein). 
Within diet-derived compounds, particular attention has to be paid to reactive 1,2-
dicarbonyl compounds, including methylglyoxal (MGO), glyoxal (GO) and 3-
deoxyglucosone (3-DG), which are formed during the early stage of Maillard reaction 
and/or through degradation of carbohydrates present in foods and beverages by 
processing, cooking and prolonged storage (Adams et al., 2008; Arena, Ballistreri & 
Fallico, 2011; Arena, Ballistreri, Tomaselli & Fallico, 2011; Degen, Hellwig, Henle, 2012; 
Hellwig, Gensberger-Reigl, Henle, Pischetsrieder, 2018). These carbonyl compounds 
can undergo several different subsequent reactions, providing a great number of 
secondary products, including Advanced Glycation End-products (AGEs). This term is 
used to describe a heterogeneous group of compounds that are formed through a series 
of non-enzymatic reactions. Excessive consumption of AGEs are thought to be 
associated with several negative health effects, which is an emerging concern for 
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processed food industries (Sharma, Kaur, Thind, Singh & Raina, 2015; Snelson & 
Coughlan, 2019). 
To the best of our knowledge, there is no data in the literature demonstrating the effect 
of pure dicarbonyl compounds on the composition of the gut microbiota and there is 
conflicting evidence regarding the impact of dietary dicarbonyl compounds, mainly from 
Manuka honey, on the composition of the gut microbiota. The ability of Manuka honey, 
characterised by antibacterial activity, is at least in part due to reactive MGO content, 
which is up to 100-fold higher than in conventional honey (Adams et al., 2008; Mavric, 
Wittmann, Barth & Henle, 2008). Consumption of Manuka honey has resulted in 
increased numbers of beneficial gut bacteria, including Lactobacillus rhamnosus and 
Bifidobacterium lactis. This effect was considered particularly advantageous because, in 
proportion to the increasing number of positive bacteria, the number of potentially 
pathogenic microorganisms in the intestine decreased (Rosendale et al., 2008). 
Rosendale et al. (2016) also affirmed that consumption of Manuka honey, which contains 
antimicrobial MGO, does not significantly perturb the microbiota in the hindgut of mice, 
but instead resulted in the production of beneficial microbial metabolites, in particular, 
short-chain fatty acids. 
The antibacterial activity of the three 1,2-dicarbonyl compounds (3-DG, GO and MGO) 
against many bacterial strains has been evaluated (Jay, Rivers & Boisvert, 1983; Mavric 
et al., 2008; Blair, Cokcetin, Harry & Carter, 2009; Hayashi, Fukushima, Hasyashi-Nishino 
& Nishino, 2014; Brighina, Restuccia, Arena, Palmeri & Fallico, 2020). These studies 
have demonstrated antibacterial activity of GO and MGO, while no growth inhibition was 
detected for 3-DG. MGO showed higher antibacterial activity than GO. Moreover, Brighina 
et al. (2020) demonstrated interactions between the dicarbonyl compounds, in particular 
MGO, and the nutrient compounds of the culture medium, highlighting that the Minimal 
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Inhibitory Concentration (MIC) values for microorganisms, under the studied conditions, 
could be significantly altered.
For the reasons mentioned above, the present study aimed to evaluate the effect of 
pure dicarbonyl compounds on the gut microbiota. Different concentrations of 3-DG, GO 
and MGO were first subjected to simulated gastrointestinal digestion, then to a pH-
controlled, anaerobic, faecal batch-culture fermentation, simulating the environmental 
conditions located in the distal region of the human large intestine. Changes in the 
bacterial population were investigated by fluorescence in situ hybridisation (FISH) and 
short-chain fatty acid (SCFA) analysis.
2. Material and methods
2.1 Chemicals
All reagents, unless otherwise stated, were from Sigma Aldrich (St. Louis, MO, 
USA); Glyoxal (GO; bioreagent 40% in H2O) Methylglyoxal (MGO; 40% in H2O). 3-
deoxyglucosone (3-DG; purity 95%) was from Santa Cruz Biotechnology, Inc. (Dallas, 
TX, USA). All nucleotide probes used for fluorescent in situ hybridisation (FISH) were 
from Eurofins, (Birmingham, UK). 
2.2 Simulated Gastrointestinal Digestion (SGD)
Simulated digestion method includes the oral, gastric and small intestinal phases 
and was used to assess the fraction of the studied molecule that passes to the anaerobic 
phases. Simulated digestion of 1,2-dicarbonyl compounds (DCs) was performed 
according to Mills et al. (2008), with slight modifications.
Water-based solutions for each of the three DCs (3-DG, MGO and GO) were 
prepared. 7.5 g of each DC aqueous solution was diluted in water (3.75 mL) and the 
mixture was stomached for 2 min. The sample solution was transferred into a glass screw-
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topped bottle, mixed with α-amylase (1 mg) in CaCl2 (0.001 mmol L-1, pH 7.0; 312.5 µL) 
and incubated at 37°C for 30 min. After, the pH was decreased to 2.0 with 6 mol L-1 HCl 
and pepsin (135 mg) dissolved in HCl (0.1 mol L-1; 1.25 mL). The sample was incubated 
at 37°C for 2 h. Then the pH was increased to 7.0 with 6 mol L-1 NaOH, pancreatin (28 
mg) bile (175 mg) in NaHCO3 (0.5 mol L-1; 6.25 mL). The sample solution was incubated 
at 37°C for 3 h.
Finally, the samples were centrifuged at 11, 620 g for 10 minutes and an aliquot of 
the supernatant was filtered through a 0.45 μm filter (Albet) and derivatised (as detailed 
in section 2.6) before DCs HPLC analysis.
2.3 Faecal sample collection and preparation
Faecal samples were collected from three different donors (1 male, 2 female, aged 
25-40 year). All donors were in good health and had not ingested any antibiotics for at 
least 6 months before the study. Samples were collected on the morning of the 
experimental fermentation. The volunteers were asked to provide these in an anaerobic 
jar (AnaerojarTM 2.5L, Oxoid Ltd), which included a gas-generating kit to maintain 
anaerobic conditions.
Within 2 hours of production, each faecal sample was diluted (1:10 w/v) with 
phosphate-buffered saline (0.1 M; pH 7.2) and homogenised in a stomacher for 2 min at 
normal speed. The obtained faecal slurries were inoculated in the batch culture vessels 
obtaining a final solution of 10% (v/v) faecal slurry. 
2.4 Batch-culture fermentation
Batch-culture fermentation was conducted to mimic physico-chemical conditions 
in the distal region of the human colon. Batch-culture fermentation vessels were sterilised 
and filled with 45 mL (in control trials and with GO and MGO standard solution; see 
8
section 2.5 for details) or 9 mL (in trials with 3-DG standard solution; see section 2.5 for 
details), of freshly steamed sterile basal nutrient medium containing peptone water (2 
g/L), yeast extract (2 g/L), NaCl (0.1 g/L), K2HPO4 (0.04 g/L), KH2PO4 (0.04 g/L), NaHCO3 
(2 g/L), MgSO4 7 H2O (0.01 g/L), CaCl2 6 H2O (0.01 g/L), Tween-80 (2 mL/L), haemin (50 
mg/L), vitamin K1, (10 μL/L), L-cysteine (0.5 g/L), bile salts (0.5 g/L), anaerobic indicator 
resazurin (1 mg/L) and distilled water. Media was gassed with a flow of O2-free N2 gas 
(15 mL/min) for a minimum of 12 h to achieve an anaerobic environment. The basal 
medium was maintained at 37°C using a circulating water bath and the pH was adjusted 
to pH 6.8 and maintained between pH 6.7 and 6.9 using an Electrolab pH controller with 
feeds of 0.5 M HCl and 0.5 M NaOH, as appropriate. Different vessels were inoculated 
with faecal slurries (5 mL for control, GO and MGO and 1 mL for 3-DG, respectively) 
resulting from each donor. 
Samples were collected at three-time points 0.1 (10 min), 8 and 24 h, for 
fluorescent in situ hybridization (FISH) and short-chain fatty acid analysis, and at four-
time points 0.1 (10 min) , 4, 8 and 24 h, for DCs HPLC analysis.
2.5 Inoculation of the substrate in batch culture fermentation
The starting concentrations of DCs used in batch culture fermentation were 
selected by considering the effect induced by SGD on each compound, to reflect the 
lowest (L) and the highest (H) levels of DCs intake with food items (Degen et al., 2012; 
Hellwig et al., 2018). The concentration of DCs inoculated in batch-culture vessels (1 mL, 
one per treatment) containing faecal slurry were the following:
3-DG: L-3DG, 54.6 mg/kg; H-3DG, 127.3 mg/kg
GO: L-GO, 4.7 mg/kg; H-GO, 23.5 mg/kg
MGO: L-MGO, 6.0 mg/kg; H-MGO, 219.6 mg/kg.
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Fermentations without DCs were conducted as a control. Moreover, to study the 
stability of DCs during the batch-culture conditions, vessels containing basal medium and 
each DCs (one per treatment) without faecal slurry were subjected to the fermentation 
conditions.
2.6 Extraction and HPLC analysis of 1,2-dicarbonyl compounds 
An aliquot of batch culture sample was centrifuged at 11,620 g for 20 min and the 
supernatant was filtered through 0.45 μm filter (Albet). An aliquot (1 mL) of the filtered 
supernatant was derivatised with a 0.2% of o-phenylenediamine (OPD) solution in water 
(Weigel, Opitz, Henle, 2004; Arena et al., 2011b). After 12 hours the derivatised mixture 
was analysed to measure the corresponding quinoxalines formed from DCs according to 
Brighina et al., (2020). The derivatised samples were injected into an HPLC series 1200 
from Agilent (Waldbronn, Germany) with a DAD (G1315B DAD) and autosampler 
(G1329A). 
The HPLC column used was a Phenomenex Kinetex, (75 mm 2.6 µ C18 100Å) 
with a prefilter: KrudKatcher Ultra HPLC In-Line Filter (0.5u Depth Filter x 0.004in ID) 
(Phenomenex, Cheshire, UK) The HPLC conditions were: eluent A was 0.1% (v/v) acetic 
acid in water and eluent B was methanol; flow rate, 0.7 mL/min; injection volume, 20 μL. 
The gradient program, where t is expressed as minutes, was: t0 85% A and 15% B; t10 
65% A and 35% B; t15 35% A and 65% B; t25 100% B; t30 85% A and 15% B. The 
detector wavelength was set to 312 nm. 
All compounds were identified by comparing retention times and UV spectra with those 
of standards and by spiking each sample with standards. Quantification of each 
compound was performed using external calibration curves. 
2.7 Bacterial enumeration 
10
To assess bacterial enumeration and the changes in the bacterial population, 
fluorescent in situ hybridisation (FISH) was used (Grimaldi et al., 2017).
750 μL of batch culture samples were centrifuged at 11,620 g for 5 min, the resulting 
pellet was fixed for a minimum of 4 h at 4°C with 375 μL of PBS and 1125 μL cold 4% 
(v/v) paraformaldehyde solution (PFA). Fixed samples were centrifuged at 11,620 g for 5 
min and washed twice with PBS (0·1 M; pH 7). Then, the remaining pellets were 
suspended in 300 μL of PBS (99 %)–ethanol mixture (1:1, v/v) and stored at -20°C for at 
least 1 h before FISH analysis.
The FISH analysis was carried out with the following two steps:
1. Permeabilisation of the bacterial cell wall: 75 µL of bacterial cell suspension was 
added to 500 µL of PBS and then centrifuged at 11,620 g for 5 min. The remaining 
pellet was added to TE-FISH containing lysozyme (1mg/mL) and incubated in the 
dark for 10 min at room temperature. Then the sample was centrifuged at 11,620 
g for 5 min, the pellet washed with 500 µL of PBS and centrifuged at 11,620 g for 
5 min.
2. In situ hybridisation: the pellet was suspended in 150 µL of hybridisation buffer 
containing NaCl (5 M), Tris/HCl (pH 8.0; 1 M), formamide, double-distilled water, 
sodium dodecyl sulphate (10%) and centrifuged at 11,620 g for 5 min. After this, 
the pellet was suspended into 1mL of hybridisation buffer. The hybridisation 
mixture (50 µl) was added into Eppendorf with 4 µL (50 ng/mL) of the appropriate 
probe and incubated overnight at 35°C. After the incubation period, the sample 
was centrifuged at 11,620 g for 5 min and the pellet was washed with 200 µL of 
wash buffer solution containing NaCl (5 M), Tris/HCl (pH 8.0; 1 M), EDTA (pH 8.0; 
0.5 M), double-distilled water and sodium dodecyl sulphate (0.01%). The sample 
was incubated for 20 min at 37°C in a heating block. After the incubation period, 
the sample was centrifuged at 11,620 g for 5 min and the pellet was suspended 
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with 300 µL of PBS and placed in the fridge at 4°C covered with aluminium foil (to 
protect samples from the light) until measurements on the cytometer (Accuri C6, 
BD Bioscience, UK).
The FISH oligonucleotides probes, hybridisation conditions and bacterial groups 
studied for enumeration are listened in Table 1.
2.8 Short-Chain Fatty Acid analysis (SCFA)
SCFA analysis was conducted using an acidification method adapted from Zhao 
et al. (2006). An aliquot of batch culture sample was centrifuged at 11,620 g for 20 min, 
and the supernatant was filtered through 0.20 μm filter (Albet). Calibration curves were 
prepared for acetic acid, propionic acid, isobutyric acid, butyric acid and valeric acid with 
a concentration between 0.5 mM and 50 mM. An aliquot (50 µL) of the filtered supernatant 
was mixed with 130 µL of H2SO4 solution (20µL of H2SO4/100 mL water) and 45 µL of 2-
ethyl butyric acid as internal standard solution. Following this 1 µL of each sample was 
injected onto the column. The CG was a 5890 SERIES II Gas Chromatograph (Hewlett 
Packard, UK) with FFAP, capillary fused silica packed column 25 m by 0.32 mm; film 
thickness, 0.25 μm (Macherey- Nagel, Düren, Germany). Calibration curves were 
constructed and internal response factors calculated and used to determine the 
concentration of metabolites within the samples.
2.9 Statistics
All data obtained were subjected to analysis of variance (ANOVA). Differences 
between sample means were considered significant at p ≤ 0.05. All statistical analyses 




3.1 Simulated Gastrointestinal Digestion (SGD)
The SGD mimics the early processes of human digestion, taking into account digestive 
enzymes, pH, time, among other factors. It has been used to assess the fraction of DCs 
passing to the next stages. 
Although 3-DG is a highly reactive compound, SGD led to a concentration loss of 11.3 
±1.3%, indicating high stability of 3-DG to digestion conditions. An effect of the SGD on 
both GO and MGO levels was also observed, with a concentration loss of 24.3%±9.5 and 
24.3% ±13.3, respectively. A study (Hamzalioğlu & Gökmen, 2016), aimed to investigate 
the gastro-duodenal digestion of biscuits in vitro, reported an average decrease in 3-DG 
levels of 16-40%, lower than MGO loss (29-68%). 
Our results suggest that in this model system, the majority of the DCs pass into the colon, 
where they could react with other substances and/or microorganisms. This, however, 
does not include the food matrix effects and the possible interactions with other food 
components.  
The concentration loss induced by SGD was used to calculate the amounts of DCs to be 
inoculated in the batch culture to simulate both the lowest and highest levels of DCs 
dietary intake (Degen et al., 2012; Hellwig et al., 2018). 
3.2 Metabolism of 1,2-dicarbonyl compounds
It is well known that DCs easily react with amino residues in proteins (cysteine, arginine, 
lysine) as well as could be trapped by aminoguanidine, creatin compounds delaying the 
AGEs formation, thus preventing the late consequences of diabetes (Thornalley, Yurek-
George & Argirov, 2000; Löbner, Degen & Henle, 2015; Hamzalioğlu & Gokmen, 2016). 
The basal nutrient medium used for the batch culture fermentation contains peptone and 
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L-cysteine that could interact with 1,2 dicarbonyl compounds during fermentation 
conditions acting as a competitor to the faecal microorganisms (Brighina et al., 2020). 
To exclude any interference by the assay system, control fermentations with the faecal 
slurry but without DCs and with DCs but without the faecal slurry were carried out. This 
was to highlight: firstly the possible formation of DCs and secondly the stability of DCs in 
the fermentation conditions (37°C, pH 6.7- 6.9). In all control samples, no DC was 
detected up to 24 h, suggesting that the fermentation conditions do not favour their 
formation (data not shown). To evaluate the metabolism of DCs by human faecal 
microbiota, samples collected up to 24 h were analysed to quantify the residual amount 
of DCs. 
Table 2 shows the changes in the residual levels of each DC during batch culture 
fermentations, with and without the presence of the faecal slurry. 
When 3-DG at the lowest concentration (L-3DG) was incubated without faecal slurry, a 
statistically significant decrease in the concentration was observed and at 24h the 
residual level was about 68%. In the system with the highest concentration of 3-DG (H-
3DG), the levels remained almost constant and no significant differences were highlighted 
up to 24h (Table 2). 
The addition of faecal slurries bring to statistically significant decrease of the 3-DG levels, 
both at the lowest and highest levels. In the batch culture with faecal slurry, 3-DG was 
rapidly metabolised with a first-order reduction, both at the lowest and highest levels. At 
the first sample timepoint (0.1, 10 min), the residual concentrations were 64 and 89% (for 
L-3DG and H-3DG, respectively). The results were different with the microbial community 
from donor 2; although at the end the 3-DG residual levels were comparable, 3-DG 
concentration was lost more slowly than with the other two donor’s samples (Table 2). 
Moreover, except for the microbiota of donor 2, it seemed that the system, independently 
of the starting 3-DG concentration, used about 20 mg/kg after 0.1 hours and 50-85 mg/kg 
14
after 8 hours of incubation. After 24 h, the residual level of 3-DG was about 0.5 and 2.0% 
in L-3DG and H-DG systems respectively. 
The GO showed a decreasing trend of its level both in the system without or with faecal 
slurry (Table 2). There was significant difference between the two systems at incubation 
time 24 h in L-GO and during the first two sampling in the H-GO. The system with GO (no 
faecal slurry) showed a significant decrease at 24 h at both concentrations. In the L-GO 
system, the residual level reduced drastically after 4 h (58.8%) and successively 
degraded until about 80% at the end of treatment (Table 2). In H-GO system, about 50% 
of the initial concentration was lost after 10 min and after 24 h the residual level was about 
6%. These results were in agreement with those reported on the interaction of the nutrient 
medium with GO (Brighina et al., 2020). The introduction of faecal microbiota did not lead 
to a further decrease in the GO residual level with the exception of L-GO system at 24h, 
whilst, the presence of faecal microbiota seemed to stabilise the GO at least until 4h in 
H-GO system. 
Great variation of residual levels of MGO was also observed, especially at the lowest 
concentration, both in the control and in the added faecal systems (Table 2). When MGO 
was added to system and batch culture no significant decrease was observed during the 
early minutes (0.1, 10 min). After 4 h of incubation without faecal microbiota, the residual 
level of MGO was greatly reduced in L-MGO systems (9.9%) and in subsequent 
samplings, MGO was completely lost. In the H-MGO system, an extensive but partial 
reduction occurred during incubation and at 24h a residual level of about 36% was found 
(Table 2). 
The initial concentration seemed to play a key role: in L-MGO, the faecal batch cultures 
had a protective effect on MGO and after 4 and 8h the residual levels were about 46 and 
22%, respectively. At both sampling times, the residual levels were significantly higher 
than those determined in the systems without faecal microbiota. At 24 h, MGO was 
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completely lost in L-MGO. In the H-MGO a progressive fermentation was highlighted and, 
after 24h of incubation, the residual level of MGO was about 14%, significantly lower than 
those determined in the systems without faecal microorganisms (Table 2). It was reported 
that the reactions between MGO and tryptone soy broth medium (TSB) are kinetically 
favoured with respect to the reaction between microorganisms and MGO (Brighina et al., 
2020).
3.3 Changes in bacterial groups during in vitro batch culture fermentation
FISH analysis, as proposed by other authors (Hidalgo et al., 2012; Alqurashi, Alarifi, 
Walton, Costabile, Rowland & Commane 2017; Grimaldi et al., 2017), was used to 
evaluate the changes in bacterial, levels and populations, induced by the three 
dicarbonyls on the faecal microbiota. Fermentation with samples from the three faecal 
donors exhibited marked differences in microbial compositions. As observed in this study, 
the donor was one of the factors that influenced the degradation of DCs during batch 
culture fermentation. Considering the great variability among individuals, it was not 
deemed appropriate to average the results of the three individuals and therefore the 
results were reported for each donor (Figures 1, 2 and 3), as suggested by Helou, Anton, 
Niquet-Léridon, Spatz, Tessier, and Gadonna-Widehem, (2015). 
Fermentation in the presence of 3-DG altered both the distribution and the level of 
microbial groups, as compared to the negative control (Fig. 1). Even at the lowest 
concentration (54.6 mg/kg), there was an effective antibacterial effect, mainly against 
Bifidobacterium spp. (BIF), Lactobacillus/Enterococcus spp. (LAB) and Bacteroides spp. 
(BAC). 3-DG also influenced the presence of Clostridium coccoides–Eubacterium rectale 
group (EREC), Roseburia spp. (RREC), Faecalibacterium prausnitzii group (FPRAU), 
Desulfovibrionales (excluding Lawsonia) and many Desulfuromonales (DSV) and C. 
histolyticum group (CHIS). The microbial reduction, relative to negative control vessels, 
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was even greater in the presence of the highest 3-DG concentration (217.7 mg/kg), 
specifically following fermentation of microbiota from donors 1 and 3, with over 5 Log10 
fewer bacteria as compared to the negative control for BAC, DSV and between 3-5 Log10 
fewer bacterial numbers per mL for LAB and CHIS (Fig 1).
GO, at the lowest concentration (4.7 mg/kg), had a negligible effect on microorganisms 
(Fig. 2). At the highest concentration, 25.5 mg/kg, there was a reduction with respect to 
the negative control vessels, of more than 1 Log10 bacterial numbers per mL. As such it 
was observed that at these concentrations gut microorganisms tolerate GO. The bacteria 
of donor 3 were less sensitive to GO (Fig. 2).
Fermentation of MGO, at the lowest concentration (6 mg/kg), led to a 1 Log10 reduction 
of bacterial numbers per mL for LAB and DSV for donors 1 and 2, compared to the 
negative control (Fig. 3). At the highest concentration (220 mg/kg) bacteria of donor 3 
were re sensitive and there was a reduction of 4-6 Log10 bacterial numbers per mL of 
LAB, BAC and FPRAU and 2 Log10 for others EREC, RREC, Clostridium cluster IX 
(PRO). Whilst the bacteria of donors 1 and 2 were less sensitive to the highest level of 
MGO resulting in 1-3 Log10 lower bacterial numbers per mL for LAB, BAC, CHIS, PRO 
and DSV as compared to the negative control (Fig. 3).
When the data was averaged, even with the great variation observed after 24 hours 
fermentation there were significantly fewer lactobacilli upon fermentation of 3-DG and 
MGO (p = 0.01 and 0.01, respectively). Furthermore 3-DG also resulted in lower levels of 
FPRAU, PRO and DSV (p = 0.03, 0.01 and 0.03, respectively).
3.4 Short Chain Fatty Acids (SCFA)
SCFA are the non-gaseous end-products of fermentation reactions formed during 
digestion (Cummings, 1981). They have been associated both with the type of digested 
carbohydrates and their concentrations. SCFA can underline an adaptive immune 
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microbiota to promote colon homeostasis and health (Morrison & Preston, 2016). Table 
S1 reports data of SCFA, for each donor and the dicarbonyl added ones. Moreover, the 
net effect of each dicarbonyl is reported as the difference between the SCFA 
concentration in the dicarbonyl and the corresponding control sample. 
The level of SCFA in the three donors samples, used as a control, confirms that in vitro 
digestion is specific for each donor. The level of all SCFA, but caproic, increased during 
the 24 hours of fermentation; this was observed for all donors for acetic and propionic 
acids. Butyric, iso-butyric and valeric acids increased only in donors 1 and 3. The 
fermentation with bacteria from donor 1 led to the highest levels of all SCFA ( 7.7 mM 
for acetic,  7 mM for butyric,  4 for valeric and  2mM for propionic and iso-butyrric 
acids) while donor 2 showed the lowest levels ( 2.5mM for acetic and 1mM for propionic 
acid).
The presence of dicarbonyl compounds modified the levels of SCFA. The addition of 3-
DG to the D1 system resulted in less SCFA as compared to the control, particularly after 
24 h at the highest 3-DG concentration. In practice, after 24h there were lower levels of 
SCFA when compared to the control. Also in the other two donors systems, there were 
less SCFA (Table S1). Therefore, the microbial community was disrupted by the 
treatment and as such the community was less able to produce the SCFA / BCFA end-
products. 
The addition of GO to the donor 1 system, at the highest concentration, adversely affected 
the gut microbiota hence the SCFA levels were lower. On the other hand, within the donor 
2 system, higher levels of SCFA were observed as compared to the corresponding control 
sample; this was particularly evident for acetic and butyric acids at the lowest GO level 
(Table S1). The GO in the donor 3 system led to the highest fermentation activity in the 
early stage (0.1 h) then declining to no net production after 24 hours. 
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The addition of MGO, almost in all of the three donor systems, slowed down SCFA 
production even at the lowest concentration. At the highest one, MGO, analogously to 
3DG, was very effective in preventing the fermentation routes to SCFA production 
throughout the fermentation (Table S1).
4. DISCUSSION
Results of SGD have indicated that the majority of the ingested DCs, about 75% of GO 
and MGO or 90% of 3-DG, are likely to pass intact through the first phase of digestion to 
the enter the large intestine. Although with some differences within the large intestine the 
DCs rapidly decrease. For example, the 3-DG was stable in control samples, with the 
absence of faecal bacteria, but degraded very quickly, with first-order kinetics, under 
anaerobic digestion conditions (faecal slurry). Both GO and MGO were unstable under 
the studied conditions in control and the faecal fermenters, with differences due to 
concentration or to the presence of the faecal slurry. This means that substantial parts of 
these molecules could be degraded already within the media, without the inclusion of 
faecal bacteria. Further studies would be necessary to highlight the ratios of GO/MGO 
reacting with each part of the system. Other in vitro studies (Daglia, Ferrari, Collina & 
Curti, 2013; Degen, Vogel, Richter, Hellwig & Henle, 2013) have shown the reaction of 
MGO with digestive enzymes. Our results are similar to those reported for high MGO 
Manuka honey (concentration loss 19-24%; Daglia et al., 2013), but much lower than 
values reported in the two cited studies for standard MGO solutions (concentration loss 
> 70%; Daglia et al., 2013) and Manuka honey (Degen et al., 2013). 
The literature largely reports the high level of dietary intake of AGEs (Advanced Glycation 
End-products) (Henle, 2003, 2005; Delgado-Andrade, 2016), and the deleterious health 
effects (Singh, Barden, Mori & Beilin, 2001; Shimizu et al., 2013). If the degradation routes 
of DCs during digestion do not lead to the formation of AGEs, this could result in them 
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passing into the colon, to be promptly degraded while exerting their antimicrobial capacity. 
On the other hand, being DCs the precursors of AGEs, if their degradation routes lead to 
AGEs, this could be a concern. Further mechanistic studies are needed. Also, the data of 
this study demonstrated that 3-DG can play a crucial role under metabolic digestion 
conditions, because of its high reactivity and large spread in cooked foods (Degen et al., 
2012) and honey (Mavric et al., 2008; Arena et al., 2011a, b). 
The antimicrobial properties of α-dicarbonyl compounds have been investigated for a long 
time (Jay et al., 1983), along with investigations on Manuka honey properties (Adams et 
al., 2008; Mavric et al., 2008; Blair et al., 2009). All these previous studies and a very 
recent one (Brighina et al., 2020) agree that 3-DG do not have, except at very high 
concentration, any antimicrobial activity. On the contrary, the FISH analysis reported in 
the present study has shown that 3-DG is the most powerful of the three studied DCs in 
reducing microbial levels under anaerobic conditions. This could help to explain the ability 
of Manuka honey at modifying both positive and negative gut bacteria, with MGO under 
the required limit to inhibit bacterial growth (Rosendale et al. 2008).
The ability of 3-DG in reducing bacterial level depended on the starting community 
provided by the donor, but it leads to a reduction of bacterial populations. 3-DG reduced 
the population of beneficial bacteria, for instance, BIF and LAB, and of BAC, EREC, and 
also DSV. The ability of 3-DG to slow down or to arrest the fermentation reactions is also 
confirmed by the SCFA levels. While SCFA level increased in the control fermentations 
during the 24 hours of fermentation, in the presence of 3-DG SCFAs levels were lower. 
In particular, it seemed that acetic and butyric acids, related to BIF, BAC (Collins & 
Gibson, 1999), EREC and FPRAU (Kim, Park & Kim, 2014) respectively, disappeared. 
Furthermore, when looking at the data as a whole 3-DG and MGO seemed effective at 
reducing numbers of lactobacilli, genera often associated with positive effects.
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With regards to GO and MGO, under the studied conditions, almost 75% of the two 
molecules can reach the colon. But, due to their high reactivity or the low starting initial 
concentration, the hypothesis of interferences by the assay system seemed to be 
confirmed (Brighina et al., 2020). Both molecules reacted very quickly with compounds 
present in the control sample (e.g., nutrient medium containing peptone, cysteine, etc.; 
see section 2.2.), making it difficult or impossible to distinguish between the fraction 
consumed by the measurement system (control) and the fraction consumed during the 
digestion processes (in the presence of faecal slurry). As a consequence, the digestion 
results concerning GO and MGO could be underestimated.
Results of the present study evidenced that all the dicarbonyls, tested at levels similar to 
food intake, were able to reduce the bacterial groups and thus exert a negative effect in 
the intestinal bacterial population, showing a direct effect on digestion processes. In 
particular for 3-DG when used at the highest concentration (127.7 mg/kg), reduced the 
population of the microbial groups tested and SCFA levels, whilst at the lowest 
concentration (54.5 mg/kg), 3-DG exerted an effective antibacterial effect against the 
positive bacteria BIF and LAB. To the best of our knowledge the antibacterial activity of 
3-DG has not previously been demonstrated. The daily intake of this compound can easily 
reach the levels tested with the common diet, since the daily food basket, containing fruit 
juices, honey, biscuits, bread and jam, can provide a 3-DG daily intake ranging from about 
36 mg up to 270 mg (Degen et al., 2012). Moreover, the ingested amounts of 3-DG 
exceed those of the other 1,2-dicarbonyl compounds by about 10-fold (Degen et al., 
2012). 
This is of particular interest because ready-to-consume hyper-palatable (ultra-processed) 
foods, that are characteristic of the Western diet and could therefore lead to a noticeable 
reduction of bacteria important to the microbiome. Many commonly consumed ultra-
processed foods, such as breakfast cereals, bread, cookies and carbohydrate-rich 
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snacks, are an important source of dicarbonyl compounds. Due to the heterogeneity and 
the multitude of reactive compounds that arise from the heat treatment of processed foods 
and their apparent contradictory effect, daily intake of these foods should be focused as 
a factor that could influence microbiota diversity and function. Also, heat-treatment of the 
food could further impact of the antimicrobial potential of these foods and as such 
warrants further investigation. 
This paper, for the first time, used realistic levels of DCs for in vitro gastrointestinal and 
fermentative digestion using isolated compounds. In successive research real foods 
should be studied to consider the effects of the food matrix and the possible interaction 
between different food components (nutrients and non-nutrients) on the antimicrobial 
potential of these components within the gut. 
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Table 1.  FISH oligonucleotides probes used and bacterial groups studied.
Probe 
name





Non Eub ACTCCTACGGGAGGCAGC No bacteria 35 Wallner et 
al. (1993)
Eub338 GCTGCCTCCCGTAGGAGT Total bacteria 35 Daims et al. 
(1999)
Eub338II GCAGCCACCCGTAGGTGT Total bacteria 35 Daims et al. 
(1999)
Eub338III GCTGCCACCCGTAGGTGT Total bacteria 35 Daims et al. 
(1999)
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. 35 Langen.dijk 
et al. (1995)
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus/Enterococcus 
spp
35 Harmsen et 
al. (1999)
Bac303 CCAATGTGGGGGACCTT Bacteroides spp 35 Manz et al. 
(1996)
Erec482 GCTTCTTAGTCARGTACCG Clostridium coccoides–
Eubacterium rectale group
35 Franks et al. 
(1998)
Rrec584 TCAGACTTGCCGYACCGC Roseburia genus 35 Walker et al. 
(2005)
Ato291 GGTCGGTCTCTCAACCC Atopobium spp 35 Harmsen et 
al. (2000)
Prop853 ATTGCGTTAACTCCGGCAC Clostridium cluster IX. 35 Walker et al. 
(2005)
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii 
group
35 Devereux et 
al. (1992)
DSV687 TACGGATTTCACTCCT Desulfovibrionales (excluding 
Lawsonia) an.d many 
Desulfuromonales
35 Hold et al. 
(2003)
Chis150 TTATGCGGTATTAATCTYCCTTT C. histolyticum group 35 Franks et al. 
(1998)
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Table 2. Residual levels percentage (average value and for each donor) of 1,2 dicarbonyl 




level Residual level % 0.1
a 4 8 24
Without faecal slurry 107.2±0.5Aa 101.1±0.6 Ab 80.3±0.3Ac 67.6±0.7Ad
+ faecal slurry 64.3±23.3Aa 54.8±13.1Ba 17.3±11.5 Bb 0.53±0.9Bc
Donor1 57.3 56.6 30.1 n.d










Donor3 45.2 40.8 7.9 nd
Without faecal slurry 126.7±10.0Aa 118.7±18.7Aa 136.0±36.0Aa 114.6±14.6Aa
+ faecal slurry 89.4±7.1Ba 67.3±6.0Bb 53.5±16.2Bc 2.03±2.1Bd
Donor1 83.9 59.4 68.8 n.d













Donor3 85.4 71.4 32.7 4.7
Without faecal slurry 130.4±16.5Aa 58.8±3.4Ab 30.2±6.3Ac 20.5±3.5Ac
+ faecal slurry 113.9±13.8 Aa 62.1±5.3 Ab 37.1±7.9 Ac 3.89±2.92Bd
Donor1 117.7 63.05 27.76 5.95










Donor3 127.60 67.71 45.62 0.97
Without faecal slurry 49.6±10.4Ba 46.4±9.8Ba 32.4±0.28Ab 6.5±0.2Ac
+ faecal slurry 115.8±14.5 Aa 64.5±6.74 Ab 31.3±5.39 Ac 9.42±2.50 Ad
Donor1 116.06 67.47 24.97 7.57












Donor3 137.18 70.42 37.35 7.94
Without faecal slurry 90.2±3.4Aa 9.9±1.0Ab 0.5±0.0Bc n.d
+ faecal slurry 91.2±26.3 Aa 46.2±21.0 Ab 21.9±18.7 Ac n.d
Donor1 119.70 74.24 44.27 n.d












Donor3 94.42 33.14 20.25 n.d
Without faecal slurry 127.2±15.3Aa 84.1±3.6Ab 53.8±5.0Ac 36.1±1.0Ad
+ faecal slurry 111.9±9.03 Aa 68.4±15.9 Ab 35.5±25.7 Ac 14.4±11.7 Bd
Donor1 116.06 47.77 50.66 15.73













Donor3 119.51 83.14 1.25 0.16
a 0.1, 10 min. Data expressed as the mean ± standard deviation. In each column, values followed by 
different capital letters within the same dicarbonyl compounds level and time and are significantly different 
according to Fisher's least significant difference test (p≤0.05). In each row, values followed by different 
lowercase letters are significantly different according to Fisher's least significant difference test (p≤0.05) 
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Figure Captions
Fig. 1. Influence of low (54.5 mg/kg) and high (127.7 mg/kg) levels of 3-DG on the gut microbiota 
of different donors (D1, D2, D3) in a pH-controlled anaerobic fermentation vessels (1% faecal 
slurry, n = 1) quantified using fluorescence in situ hybridisation. Samples were collected at time 
(T) 0.1 (10 min), 8, and 24 h. Bacterial name: TOTAL: Total bacteria; BIF: Bifidobacterium spp.; 
LAB: Lactobacillus/Enterococcus spp; BAC: Bacteroides spp; EREC: Clostridium coccoides– 
Eubacterium rectale group; RREC: Roseburia genus; ATO: Atopobium spp; PRO: Clostridium 
cluster IX; FPRAU: Faecalibacterium prausnitzii group; DSV: Desulfovibrionales (excluding 
Lawsonia) and many Desulfuromonales; CHIS: C. histolyticum group. Changes in bacterial 
growth calculated by comparing the number of a specific bacterial group in the treatment with the 
number found in a control group, at the same time point.
Fig. 2. Influence of low (4.07 mg/kg) and high (25.5 mg/kg) levels GO on the gut microbiota of 
different donors (D1, D2, D3) in a pH-controlled anaerobic fermentation vessels (1% faecal slurry, 
n = 1) quantified using fluorescence in situ hybridisation. Samples were collected at time (T) 0.1 
(10 min), 8, and 24 h. Bacterial name:TOTAL: Total bacteria; BIF: Bifidobacterium spp.; LAB: 
Lactobacillus/Enterococcus spp; BAC: Bacteroides spp; EREC: Clostridium coccoides– 
Eubacterium rectale group; RREC: Roseburia genus; ATO: Atopobium spp; PRO: Clostridium 
cluster IX; FPRAU: Faecalibacterium prausnitzii group; DSV: Desulfovibrionales (excluding 
Lawsonia) and many Desulfuromonales; CHIS: C. histolyticum group. Changes in bacterial 
growth calculated by comparing the number of a specific bacterial group in the treatment with the 
number found in a control group, at the same time point.
Fig. 3. Influence of low (6.04 mg/kg) and high (219.6 mg/kg) levels of MGO on the gut microbiota 
of different donors (D1, D2, D3) in a pH-controlled anaerobic fermentation vessels (1% faecal 
slurry, n = 1) quantified using fluorescence in situ hybridisation. Samples were collected at time 
(T) 0.1 (10 min), 8, and 24 h. Bacterial name:TOTAL: Total bacteria; BIF: Bifidobacterium spp.; 
LAB: Lactobacillus/Enterococcus spp; BAC: Bacteroides spp; EREC: Clostridium coccoides– 
Eubacterium rectale group; RREC: Roseburia genus; ATO: Atopobium spp; PRO: Clostridium 
cluster IX; FPRAU: Faecalibacterium prausnitzii group; DSV: Desulfovibrionales (excluding 
Lawsonia) and many Desulfuromonales; CHIS: C. histolyticum group. Changes in bacterial 
growth calculated by comparing the number of a specific bacterial group in the treatment with the 
number found in a control group, at the same time point.
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Highlights:
 GO, MGO and 3-DG withstand in vitro gastrointestinal digestion 
 Digested 1,2-dicarbonyl compounds reduce number and activity of gut 
microorganisms
 For the first time, the role of 3-DG in modifying the gut microbial levels has been 
shown
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 1,2-dicarbonyls reduce the levels of Short Chain Fatty Acids produced during 
fermentation
Table 1.  FISH oligonucleotides probes used and bacterial groups studied.
Probe 
name





Non Eub ACTCCTACGGGAGGCAGC No bacteria 35 Wallner et 
al. (1993)
Eub338 GCTGCCTCCCGTAGGAGT Total bacteria 35 Daims et al. 
(1999)
Eub338II GCAGCCACCCGTAGGTGT Total bacteria 35 Daims et al. 
(1999)
Eub338III GCTGCCACCCGTAGGTGT Total bacteria 35 Daims et al. 
(1999)
Bif164 CATCCGGCATTACCACCC Bifidobacterium spp. 35 Langen.dijk 
et al. (1995)
Lab158 GGTATTAGCAYCTGTTTCCA Lactobacillus/Enterococcus 
spp
35 Harmsen et 
al. (1999)
Bac303 CCAATGTGGGGGACCTT Bacteroides spp 35 Manz et al. 
(1996)
Erec482 GCTTCTTAGTCARGTACCG Clostridium coccoides–
Eubacterium rectale group
35 Franks et al. 
(1998)
Rrec584 TCAGACTTGCCGYACCGC Roseburia genus 35 Walker et al. 
(2005)
Ato291 GGTCGGTCTCTCAACCC Atopobium spp 35 Harmsen et 
al. (2000)
Prop853 ATTGCGTTAACTCCGGCAC Clostridium cluster IX. 35 Walker et al. 
(2005)
Fprau655 CGCCTACCTCTGCACTAC Faecalibacterium prausnitzii 
group
35 Devereux et 
al. (1992)
DSV687 TACGGATTTCACTCCT Desulfovibrionales (excluding 
Lawsonia) an.d many 
Desulfuromonales
35 Hold et al. 
(2003)
Chis150 TTATGCGGTATTAATCTYCCTTT C. histolyticum group 35 Franks et al. 
(1998)
33
Table 2. Residual levels percentage (average value and for each donor) of 1,2 dicarbonyl 




level Residual level % 0.1
a 4 8 24
Without faecal slurry 107.2±0.5Aa 101.1±0.6 Ab 80.3±0.3Ac 67.6±0.7Ad
+ faecal slurry 64.3±23.3Aa 54.8±13.1Ba 17.3±11.5 Bb 0.53±0.9Bc
Donor1 57.3 56.6 30.1 n.d










Donor3 45.2 40.8 7.9 nd
Without faecal slurry 126.7±10.0Aa 118.7±18.7Aa 136.0±36.0Aa 114.6±14.6Aa
+ faecal slurry 89.4±7.1Ba 67.3±6.0Bb 53.5±16.2Bc 2.03±2.1Bd
Donor1 83.9 59.4 68.8 n.d













Donor3 85.4 71.4 32.7 4.7
Without faecal slurry 130.4±16.5Aa 58.8±3.4Ab 30.2±6.3Ac 20.5±3.5Ac
+ faecal slurry 113.9±13.8 Aa 62.1±5.3 Ab 37.1±7.9 Ac 3.89±2.92Bd
Donor1 117.7 63.05 27.76 5.95










Donor3 127.60 67.71 45.62 0.97
Without faecal slurry 49.6±10.4Ba 46.4±9.8Ba 32.4±0.28Ab 6.5±0.2Ac
+ faecal slurry 115.8±14.5 Aa 64.5±6.74 Ab 31.3±5.39 Ac 9.42±2.50 Ad
Donor1 116.06 67.47 24.97 7.57












Donor3 137.18 70.42 37.35 7.94
Without faecal slurry 90.2±3.4Aa 9.9±1.0Ab 0.5±0.0Bc n.d
+ faecal slurry 91.2±26.3 Aa 46.2±21.0 Ab 21.9±18.7 Ac n.d
Donor1 119.70 74.24 44.27 n.d












Donor3 94.42 33.14 20.25 n.d
Without faecal slurry 127.2±15.3Aa 84.1±3.6Ab 53.8±5.0Ac 36.1±1.0Ad
+ faecal slurry 111.9±9.03 Aa 68.4±15.9 Ab 35.5±25.7 Ac 14.4±11.7 Bd
Donor1 116.06 47.77 50.66 15.73













Donor3 119.51 83.14 1.25 0.16
a 0.1, 10 min. Data expressed as the mean ± standard deviation. In each column, values followed by 
different capital letters within the same dicarbonyl compounds level and time and are significantly different 
according to Fisher's least significant difference test (p≤0.05). In each row, values followed by different 





Fig. 1. Influence of low (54.5 mg/kg) and high (127.7 mg/kg) levels of 3-DG on the gut microbiota 
of different donors (D1, D2, D3) in a pH-controlled anaerobic fermentation vessels (1% faecal 
slurry, n = 1) quantified using fluorescence in situ hybridisation. Samples were collected at time 
(T) 0.1 (10 min), 8, and 24 h. Bacterial name: TOTAL: Total bacteria; BIF: Bifidobacterium spp.; 
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LAB: Lactobacillus/Enterococcus spp; BAC: Bacteroides spp; EREC: Clostridium coccoides– 
Eubacterium rectale group; RREC: Roseburia genus; ATO: Atopobium spp; PRO: Clostridium 
cluster IX; FPRAU: Faecalibacterium prausnitzii group; DSV: Desulfovibrionales (excluding 
Lawsonia) and many Desulfuromonales; CHIS: C. histolyticum group. Changes in bacterial 
growth calculated by comparing the number of a specific bacterial group in the treatment with the 





Fig. 2. Influence of low (4.07 mg/kg) and high (25.5 mg/kg) levels GO on the gut microbiota of 
different donors (D1, D2, D3) in a pH-controlled anaerobic fermentation vessels (1% faecal slurry, 
n = 1) quantified using fluorescence in situ hybridisation. Samples were collected at time (T) 0.1 
(10 min), 8, and 24 h. Bacterial name: TOTAL: Total bacteria; BIF: Bifidobacterium spp.; LAB: 
Lactobacillus/Enterococcus spp; BAC: Bacteroides spp; EREC: Clostridium coccoides– 
Eubacterium rectale group; RREC: Roseburia genus; ATO: Atopobium spp; PRO: Clostridium 
cluster IX; FPRAU: Faecalibacterium prausnitzii group; DSV: Desulfovibrionales (excluding 
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Lawsonia) and many Desulfuromonales; CHIS: C. histolyticum group. Changes in bacterial 
growth calculated by comparing the number of a specific bacterial group in the treatment with the 
number found in a control group, at the same time point.
.   
  
  
Fig. 3. Influence of low (6.04 mg/kg) and high (219.6 mg/kg) levels of MGO on the gut microbiota 
of different donors (D1, D2, D3) in a pH-controlled anaerobic fermentation vessels (1% faecal 
slurry, n = 1) quantified using fluorescence in situ hybridisation. Samples were collected at time 
(T) 0.1 (10 min), 8, and 24 h. Bacterial name: TOTAL: Total bacteria; BIF: Bifidobacterium spp.; 
LAB: Lactobacillus/Enterococcus spp; BAC: Bacteroides spp; EREC: Clostridium coccoides– 
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Eubacterium rectale group; RREC: Roseburia genus; ATO: Atopobium spp; PRO: Clostridium 
cluster IX; FPRAU: Faecalibacterium prausnitzii group; DSV: Desulfovibrionales (excluding 
Lawsonia) and many Desulfuromonales; CHIS: C. histolyticum group. Changes in bacterial 
growth calculated by comparing the number of a specific bacterial group in the treatment with the 
number found in a control group, at the same time point.
